Axon Enterprise Inc.

Selling some shares in this stock makes sense following a big move.

The Osterweis Emerging Opportunity Fund has an annualized return of 6.69% for the five years through Aug. 25.

It could be a good time to add these stocks to portfolios.

It may be time to buy these two stocks after their post-EPS pullbacks.

The deal is part of Axovant's strategy to focus on neurological gene therapies.

Jim Cramer takes a closer look at Okta, Celgene, GasLog Partners, Neutral Tandem, Altria, Axovant Sciences, Lowe's and more.

Jim Cramer says investors need to be cautious, as trade tensions are just one of the things causing markets to whiplash. But he's got your game plan for next week.

The Nasdaq sets a record closing high for three straight sessions.

Stocks rise Monday as equities rebound from their worst week in two years.

Chief executive David Hung resigned from the Basel, Switzerland, biotech after just 10 months on the job.

Even with Monday's sharp reversal, Jim Cramer says he still likes this market.

Softbank founder Masayoshi Son is placing big bets on artificial intelligence applications from chips to cars to workplace chats. He'll likely need more than one $100 billion fund to do it.

Axovant shares were up in premarket trading on Sept. 27 after plummeting on Tuesday on the heels of the announcement that the company's Phase 3 study of intepirdine in patients with Alzheimer's disease did not achieve its co-primary efficacy endpoints.

The company said Tuesday its Phase 3 study of intepirdine in patients with Alzheimer's disease did not achieve its co-primary efficacy endpoints.Meanwhile, shares of Genocea Biosciences Inc. were down, after the Cambridge, Mass.-based company announced a shift to immuno-oncology and a focus on developing neoantigen cancer vaccines.

Carnival shares jump after beating quarterly estimates but Adidas stock slumped following an investigation into a NCAA Bribery Scandal.

Stocks are higher. Here's how the market is trading in the afternoon session on Tuesday.

Top names.

OncoMed Pharmaceuticals, Geron and Akorn were among the biotech stock movers in premarket trading on Monday.

David Hung will become Axovant's CEO after completing the $14 billion sale of Medivation to Pfizer.

Opportunities with AI and rising spending are offset by the technical setup… for now.

Learnings we intend to utilize as we move into 2025.

Let's dive into prices and what they mean -- and don't mean -- for the Fed's rate cut; also, MicroStrategy and Palantir among names slated for Nasdaq 100; and let's chart the markets.

The software provider seems to be building a bearish pattern after being denied entry into the power index.

While year-end talk grows, we’re more focused on the coming quarters.

Here’s our plan for the shares and our thinking if a short squeeze emerges.

Short squeezes can be violent in that they can drive a stock’s price significantly higher.

Who took big profits? We took big profits. You can, too!

Even as TheStreet Pro Portfolio benefits and outperforms, market gains have key indicators flirting with overbought levels.

Chris recaps the series of moves in the portfolio this week, the reasoning behind today's trade, and previews a new Sunday feature.

As a short squeeze further extends the shares, we’ll place them in the Bullpen for future consideration.

Plus, the October ISM Services report shows the economy and jobs market remain vibrant.

Plus, what Wall Street has to say about some of our holdings (and it’s all good news).

We came into October looking for opportunities and we found several.

Cautious outlook may trigger some price target cuts, but we see the logic in the move, and here’s where we’d be buyers.

Here's what we're anticipating as investors sentiment knocks on "extreme greed."

It was a busy week of moves for the poretfolio, and we’re at the ready for more opportunities as earnings season accelerates.

We are also downgrading our rating following the pronounced move and extended valuation.

These factors have us keeping our panic points wider than usual.

The retailer is struggling to combat a growing issue.

Global travel agency platform files for bankruptcy facing industry headwinds.

TikTok's future in the United States depends entirely on the incoming president's support. President-elect Trump will be pushing for investors to see his show.